Isis Wins $5M from GSK with Launch of First Phase I Study

Isis has received a multi-million dollar milestone payment from its pharma partner GlaxoSmithKline (GSK) for the launch of the Phase I trial of the biotech’s antisense drug for transthyretin amyloidosis, one of six therapeutic programs in its alliance with GSK. Isis has also partnered with Genzyme to advance its antisense ALS therapy, currently being investigated in a Phase I clinical trial.

Click here to read more.

Share this: